RTOG 0924, “Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial,” will close to accrual at 5 PM ET Monday June 24, 2019, because it has reached its accrual target.


Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.


Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

This message was sent from to
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.